Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Mutational Phasing: Clinical Relevance in Tyrosine Kinase Domain Mutations Using Next Generation Sequencing in Chronic Myeloid Leukemia

Seema S. Bhatwadekar, MD, Parth Shah, MD

Blood (2018) 132 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2018-99-114130

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Prajwal Chaitanya Boddu, MD, Hagop M. Kantarjian, MD, Abdul Rashid Shah, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Nitin Jain, MD, Ahmad Alhuraiji, MD MRCP, Jan Burger, MD PhD, Steven M. Kornblau, MD, Sara Emogene Dellasala, BS, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 3073.

https://doi.org/10.1182/blood.V128.22.3073.3073

Published: 2016

Journal Articles

Hydroxychloroquine Sensitizes Chronic Myeloid Cell to γ9δ2T Cell Mediated Lysis Independent of Autophagy

Biqing Han, Yanmin Zhao, Yu Lin, Limengmeng Wang, Binsheng Wang, Ruxiu Tie, Yan Long, Mingming Zhang, He Huang, MD PhD

Blood (2016) 128 (22): 4244.

https://doi.org/10.1182/blood.V128.22.4244.4244

Published: 2016

Journal Articles

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, MSc, Soili Kytölä, PhD, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1924.

https://doi.org/10.1182/blood.V128.22.1924.1924

Published: 2016

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Barbara Peter, DVM, Gregor Eisenwort, Gabriele Stefanzl, Daniela Berger, Wolfgang R Sperr, MD, Johannes Zuber, MD PhD, Peter Valent, MD

Blood (2015) 126 (23): 1571.

https://doi.org/10.1182/blood.V126.23.1571.1571

Published: 2015

Journal Articles

Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance

O'Hare Thomas, PhD, Matthew S. Zabriskie, Christopher A. Eide, Nadeem A. Vellore, PhD, Brian J. Druker, MD, Michael W Deininger, MD PhD

Blood (2015) 126 (23): 1565.

https://doi.org/10.1182/blood.V126.23.1565.1565

Published: 2015

Journal Articles

Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation

Aleem Aamer, MBBS, FRCP, FRCPath, Fatmah Al Wusibai, MBBS, Khalid AlSaleh, MBBS, FRCPC, MRCP, Fatma Alqahtani, MBBS, KSU fellowship, Zafar Iqbal, PhD, Naeem A. Chaudhri, MD FACP, Abdul Kareem M Al-Momen, MD FRCPC

Blood (2015) 126 (23): 5153.

https://doi.org/10.1182/blood.V126.23.5153.5153

Published: 2015

Journal Articles

Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

Tarcila S Datoguia, MD, Hugo R C Silva, MD, Amauri M C R Junior, MD, José Salvador Oliveira, PhD, Monika Conchon, MD PhD

Blood (2015) 126 (23): 5173.

https://doi.org/10.1182/blood.V126.23.5173.5173

Published: 2015

Journal Articles

Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

Blood (2014) 124 (21): 798.

https://doi.org/10.1182/blood.V124.21.798.798

Published: 2014

Journal Articles

The BCL-2 Inhibitor ABT-199 Enhances Imatinib-Induced Cell Death In Chronic Phase CML Progenitors

Tun Kiat Ko, PhD, Charles Chuah, MD, John Huang, King-Pan Ng, PhD, S. Tiong Ong, MD

Blood (2013) 122 (21): 3978.

https://doi.org/10.1182/blood.V122.21.3978.3978

Published: 2013

Journal Articles

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Matthew Koshy, MD, Bulent Aydogan, PhD, Nadim Mahmud, MD, PhD, David Peace, MD, John G. Quigley, MD, Santosh L. Saraf, MD, Enzo DeMasi, MD, Ralph R Weichselbaum, MD, Damiano Rondelli, MD

Blood (2013) 122 (21): 3285.

https://doi.org/10.1182/blood.V122.21.3285.3285

Published: 2013

Journal Articles

Single Cell Analysis Of Protein Phosphorylation In Chronic Myeloid Leukemia Treated With Dasatinib, Eltrombopag, and Pegfilgrastim

Bjorn T Gjertsen, MD PhD, Stein E Gullaksen, MSc, Jorn Skavland, PhD, Mihaela Lucia Popa, VMD, Roald Lindas, MD, Randi Hovland, PhD, Klaus Beiske, MD, Henrik Hjorth-Hansen, MD, PhD, Emmet McCormack, PhD

Blood (2013) 122 (21): 1492.

https://doi.org/10.1182/blood.V122.21.1492.1492

Published: 2013

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

NARROW

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Mutational Phasing: Clinical Relevance in Tyrosine Kinase Domain Mutations Using Next Generation Sequencing in Chronic Myeloid Leukemia

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Hydroxychloroquine Sensitizes Chronic Myeloid Cell to γ9δ2T Cell Mediated Lysis Independent of Autophagy

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance

Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation

Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

The BCL-2 Inhibitor ABT-199 Enhances Imatinib-Induced Cell Death In Chronic Phase CML Progenitors

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Single Cell Analysis Of Protein Phosphorylation In Chronic Myeloid Leukemia Treated With Dasatinib, Eltrombopag, and Pegfilgrastim

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only